FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987604016> ?p ?o ?g. }

• W2987604016 endingPage "4413" @default.
• W2987604016 startingPage "4413" @default.
• W2987604016 abstract "The BCL-2 inhibitor venetoclax has begun to change the landscape of therapy for diverse blood cancers. Combining venetoclax with standard of care agents has led to impressive response rates, and increased depth and durability of response compared to monotherapy. However, there is a continuing need to develop safe and effective combinations in multiple myeloma (MM), where the BELLINI triple combination trial (venetoclax-dexamethasone-bortezomib) was closed to accrual due to adverse events. We reported that HMG-CoA-reductase inhibitors (statins), a safe and widely prescribed class of drugs, enhance the efficacy of venetoclax in human leukemia and lymphoma cell lines and in a retrospective study of patients with chronic lymphocytic leukemia (JS Lee et al., Sci. Transl. Med.2018, 10(445)). In MM, the subset with t11;14 translocation is BCL-2-dependent and sensitive to venetoclax, whereas other MM subtypes are more dependent on MCL-1. Here we show that statins sensitize MM cell lines and primary cells to killing by either venetoclax or the MCL-1 inhibitor S63845. The compound pitavastatin is particularly potent, active in vitro at a concentration (100 - 300 nM) that is clinically achievable. In OPM2 cells, pitavastatin synergizes with venetoclax and increases apoptosis in triple combination with dexamethasone. Pitavastatin also potentiates venetoclax killing in dexamethasone-resistant MM1R cells. In MCL-1-dependent MM cells, statins increase sensitivity to S63845. Notably, statins do not increase killing of normal human lymphocytes by either venetoclax or S63845. Statin responsiveness in MM cell lines correlates with p53-independent upregulation of PUMA, BAX and BAK, and gene editing experiments suggest that all three contribute to the apoptotic mechanism. Statin-induced apoptosis and PUMA expression are rescued by addition of geranylgeranyl-pyrophosphate, and recapitulated by an inhibitor of geranylgeranyl-transferase I. Together these findings establish a mechanistic framework to explain how statins promote apoptosis by BH3 mimetic drugs like venetoclax and S63845. Further, these results highlight the potential of statins to enhance therapeutic efficacy of BCL-2 and MCL-1 inhibitor regimens in MM, with possibly lesser toxicity than other combination strategies. Disclosures Boise: Genentech Inc.: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Research Funding. OffLabel Disclosure: Venetoclax is a BCL-2 inhibitor that is approved for some indications. I will discuss the use of venetoclax for multiple myeloma, a disease for which venetoclax is not approved." @default.
• W2987604016 created "2019-11-22" @default.
• W2987604016 creator A5004426625 @default.
• W2987604016 creator A5038076013 @default.
• W2987604016 creator A5046430988 @default.
• W2987604016 creator A5074403078 @default.
• W2987604016 creator A5079995802 @default.
• W2987604016 creator A5088834304 @default.
• W2987604016 date "2019-11-13" @default.
• W2987604016 modified "2023-10-18" @default.
• W2987604016 title "Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845" @default.
• W2987604016 doi "https://doi.org/10.1182/blood-2019-131218" @default.
• W2987604016 hasPublicationYear "2019" @default.
• W2987604016 type Work @default.
• W2987604016 sameAs 2987604016 @default.
• W2987604016 citedByCount "0" @default.
• W2987604016 crossrefType "journal-article" @default.
• W2987604016 hasAuthorship W2987604016A5004426625 @default.
• W2987604016 hasAuthorship W2987604016A5038076013 @default.
• W2987604016 hasAuthorship W2987604016A5046430988 @default.
• W2987604016 hasAuthorship W2987604016A5074403078 @default.
• W2987604016 hasAuthorship W2987604016A5079995802 @default.
• W2987604016 hasAuthorship W2987604016A5088834304 @default.
• W2987604016 hasBestOaLocation W29876040161 @default.
• W2987604016 hasConcept C126322002 @default.
• W2987604016 hasConcept C185592680 @default.
• W2987604016 hasConcept C203014093 @default.
• W2987604016 hasConcept C2776364478 @default.
• W2987604016 hasConcept C2776692505 @default.
• W2987604016 hasConcept C2776839432 @default.
• W2987604016 hasConcept C2777478702 @default.
• W2987604016 hasConcept C2777938653 @default.
• W2987604016 hasConcept C2778461978 @default.
• W2987604016 hasConcept C2779675984 @default.
• W2987604016 hasConcept C2780401358 @default.
• W2987604016 hasConcept C502942594 @default.
• W2987604016 hasConcept C71924100 @default.
• W2987604016 hasConcept C98274493 @default.
• W2987604016 hasConceptScore W2987604016C126322002 @default.
• W2987604016 hasConceptScore W2987604016C185592680 @default.
• W2987604016 hasConceptScore W2987604016C203014093 @default.
• W2987604016 hasConceptScore W2987604016C2776364478 @default.
• W2987604016 hasConceptScore W2987604016C2776692505 @default.
• W2987604016 hasConceptScore W2987604016C2776839432 @default.
• W2987604016 hasConceptScore W2987604016C2777478702 @default.
• W2987604016 hasConceptScore W2987604016C2777938653 @default.
• W2987604016 hasConceptScore W2987604016C2778461978 @default.
• W2987604016 hasConceptScore W2987604016C2779675984 @default.
• W2987604016 hasConceptScore W2987604016C2780401358 @default.
• W2987604016 hasConceptScore W2987604016C502942594 @default.
• W2987604016 hasConceptScore W2987604016C71924100 @default.
• W2987604016 hasConceptScore W2987604016C98274493 @default.
• W2987604016 hasIssue "Supplement_1" @default.
• W2987604016 hasLocation W29876040161 @default.
• W2987604016 hasOpenAccess W2987604016 @default.
• W2987604016 hasPrimaryLocation W29876040161 @default.
• W2987604016 hasRelatedWork W1999070664 @default.
• W2987604016 hasRelatedWork W2044351324 @default.
• W2987604016 hasRelatedWork W2330049167 @default.
• W2987604016 hasRelatedWork W2776297842 @default.
• W2987604016 hasRelatedWork W2953682632 @default.
• W2987604016 hasRelatedWork W4205394967 @default.
• W2987604016 hasRelatedWork W4241469660 @default.
• W2987604016 hasRelatedWork W4294719323 @default.
• W2987604016 hasRelatedWork W4313857557 @default.
• W2987604016 hasRelatedWork W3032664604 @default.
• W2987604016 hasVolume "134" @default.
• W2987604016 isParatext "false" @default.
• W2987604016 isRetracted "false" @default.
• W2987604016 magId "2987604016" @default.
• W2987604016 workType "article" @default.